Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 12/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012674 | 0.79 | LOXL2 (0.63) | LOXL2KDM4ENPSR1IDO1LMNA | |
| SCHEMBL14995335 | 0.79 | LOXL2 (0.62) | LOXL2KDM4ENPC1ALOX12HTT | |
| SCHEMBL5017627 | 0.78 | MAPT (0.48) | LOXL2KDM4EHTTIDO1LMNA | |
| SCHEMBL14075114 | 0.77 | KDM4E (0.36) | LOXL2KDM4ENPC1ALOX12HTT | |
| SCHEMBL15415316 | 0.76 | KDM4E (0.53) | LOXL2KDM4ENPC1ALOX12HTT | |
| SCHEMBL15414568 | 0.75 | KDM4E (0.37) | KDM4ENPC1ALOX12HTTRAB9A | |
| SCHEMBL8372588 | 0.75 | GSK3A (0.40) | LOXL2KDM4ENPC1ALOX12HTT | |
| SCHEMBL3151202 | 0.75 | LOXL2 (0.38) | LOXL2KDM4ENPC1ALOX12HTT | |
| SCHEMBL5012717 | 0.73 | IDO1 (0.35) | IDO1 | |
| SCHEMBL12844167 | 0.72 | GRM5 (0.40) | LOXL2KDM4ENPC1L3MBTL1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | LOXL2 4503/4885KDM4E 2778/4885NPC1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.